Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 17, 2024

Study Completion Date

July 17, 2024

Conditions

Recurrent Endometrial Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy

Trial Locations (1)

Yale New Haven Hospital, New Haven

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yale University

OTHER

NCT02899793 - Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | Biotech Hunter | Biotech Hunter